trending Market Intelligence /marketintelligence/en/news-insights/trending/11siXunesiTdvYWirc9LxA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Roche's Tecentriq combo shows jump in survival under phase 3 skin cancer trial

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Roche's Tecentriq combo shows jump in survival under phase 3 skin cancer trial

Roche Holding AG said adding Tecentriq, or atezolizumab, to its existing medicines Zelboraf and Cotellic reduced the risk of disease progression or death in patients with a certain type of skin cancer.

The company and its unit Genentech Inc. studied the medicine in a late-stage study called IMspire150, which met its primary endpoint of improving progression-free survival when compared to placebo. The phase 3 trial enrolled previously untreated melanoma patients with the BRAF V600 mutation whose disease had spread to other parts of the body or could not be removed through surgery.

Roche co-developed Cotellic, or cobimetinib, with Exelixis Inc. A combination of Tecentriq and Cotellic previously failed to extend the lives of patients with untreated advanced melanoma who have no known mutation in their BRAF V600 gene.

Zelboraf is also known as vemurafenib.